MAP7 and acute myeloid leukemia: High expression of MAP7 (also known as ensconsin or E-MAP-115) has been reported to be an adverse prognostic biomarker for cytogenetically normal acute myeloid leukemia, stage II colon cancer, cervical cancer and metastatic endometrial cancer.39